Kumar, S. Okay. et al. Danger of development and survival in a number of myeloma relapsing after remedy with IMiDs and bortezomib: a multicenter worldwide myeloma working group research. Leukemia 26, 149–157 (2012).
Carpenter, R. O. et al. B-cell maturation antigen is a promising goal for adoptive T-cell remedy of a number of myeloma. Clin. Most cancers Res. 19, 2048–2060 (2013).
Moreaux, J. et al. BAFF and APRIL defend myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103, 3148–3157 (2004).
Novak, A. J. et al. Expression of BCMA, TACI, and BAFF-R in a number of myeloma: a mechanism for progress and survival. Blood 103, 689–694 (2004).
Blenrep (belantamab mafodotin-blmf) [package insert] (GlaxoSmithKline Mental Property Growth Ltd, 2022).
Shah, N., Chari, A., Scott, E., Mezzi, Okay. & Usmani, S. Z. B-cell maturation antigen (BCMA) in a number of myeloma: rationale for concentrating on and present therapeutic approaches. Leukemia 34, 985–1005 (2020).
Usmani, S. Z. et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in sufferers with relapsed or refractory a number of myeloma (MajesTEC-1): a multicentre, open-label, single-arm, part 1 research. Lancet 398, 665–674 (2021).
Abcema (idecabtagene vicleucel) [package insert] (Celgene Company, 2021).
Carvykti (ciltacabtagene autoleucel) [package insert] (Janssen Biotech, Inc., 2022).
Lonial, S. et al. Long term outcomes with single-agent belantamab mafodotin in sufferers with relapsed or refractory a number of myeloma: 13-month follow-up from the pivotal DREAMM-2 research. Most cancers 127, 4198–4212 (2021).
Moreau, P. et al. Teclistamab in relapsed or refractory a number of myeloma. N. Engl. J. Med. 387, 495–505 (2022).
Mailankody, S. & Landgren, O. T-cell engagers—fashionable immune-based therapies for a number of myeloma. N. Engl. J. Med. 387, 558–561 (2022).
Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory a number of myeloma. N. Engl. J. Med. 384, 705–716 (2021).
Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell remedy in sufferers with relapsed or refractory a number of myeloma (CARTITUDE-1): a part 1b/2 open-label research. Lancet 398, 314–324 (2021).
Garcia-Guerrero, E., Sierro-Martinez, B. & Perez-Simon, J. A. Overcoming chimeric antigen receptor (CAR) modified T-cell remedy limitations in a number of myeloma. Entrance. Immunol. 11, 1128 (2020).
Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering methods to beat the present roadblocks in CAR T cell remedy. Nat. Rev. Clin. Oncol. 17, 147–167 (2020).
Chen, A. ‘How do you resolve?’: Most cancers therapy’s CAR-T disaster has sufferers dying on a waitlist. STAT https://www.statnews.com/2022/06/02/car-t-crisis-cancer-patients-die-waiting (2022).
Dhakal, B., Chhabra, S., Savani, B. N. & Hamadani, M. Promise and pitfalls of allogeneic chimeric antigen receptor remedy in plasma cell and lymphoid malignancies. Br. J. Haematol. 197, 28–40 (2022).
Benjamin, R. et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and grownup B-cell acute lymphoblastic leukaemia: outcomes of two part 1 research. Lancet 396, 1885–1894 (2020).
Hua, J. et al. Donor-derived anti-CD19 CAR T cells in contrast with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 56, 1056–1064 (2021).
Sommer, C. et al. Preclinical analysis of allogeneic CAR T cells concentrating on BCMA for the therapy of a number of myeloma. Mol. Ther. 27, 1126–1138 (2019).
Sommer, C. et al. Allogeneic FLT3 CAR T cells with an off-switch exhibit potent exercise towards AML and may be depleted to expedite bone marrow restoration. Mol. Ther. 28, 2237–2251 (2020).
Martin, T. et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell remedy, for relapsed/refractory a number of myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. https://doi.org/10.1200/jco.22.00842 (2022).
Harrison, S. J. et al. A part 1 first in human (FIH) research of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life prolonged (HLE) BiTE® (bispecific T-cell engager) molecule, in relapsed/refractory (RR) a number of myeloma (MM). Blood 136, 28–29 (2020).
Rafae, A. et al. Latest updates on bispecific T-cell engager (BiTE) antibodies in relapsed and refractory a number of myeloma. J. Clin. Oncol. 39, e20034–e20034 (2021).
Neelapu, S. S. et al. ALPHA Examine: ALLO-501 produced deep and sturdy responses in sufferers with relapsed/refractory non-Hodgkin’s lymphoma similar to autologous CAR T. Blood 138, 3878–3878 (2021).
Nastoupil, L. J. et al. P1455: first-in-human trial of CB-010, a crispr-edited allogeneic anti-CD19 CAR-T cell remedy with a PD-1 knock out, in sufferers with relapsed or refractory B cell non-Hodgkin lymphoma (ANTLER STUDY). HemaSphere 6(Suppl), 1337–1338 (2022).
Prevention and Remedy of Most cancers-Associated Infections (Model 3.2022). NCCN Scientific Follow Tips in Oncology, Vol. 2022 (Nationwide Complete Most cancers Community, 2022).
Sassine, J. et al. Refractory and resistant cytomegalovirus after hematopoietic cell transplant within the letermovir major prophylaxis period. Clin. Infect. Dis. 73, 1346–1354 (2021).
Lancman, G. et al. Bispecific antibodies in a number of myeloma: current and future. Blood Most cancers Discov. 2, 423–433 (2021).
Lonial, S. et al. Belantamab mafodotin for relapsed or refractory a number of myeloma (DREAMM-2): a two-arm, randomised, open-label, part 2 research. Lancet Oncol. 21, 207–221 (2020).
Maybury, B., Cook dinner, G., Pratt, G., Yong, Okay. & Ramasamy, Okay. Augmenting autologous stem cell transplantation to enhance outcomes in myeloma. Biol. Blood Marrow Transpl. 22, 1926–1937 (2016).
Nooka, A. Okay. et al. Belantamab mafodotin together with novel brokers in relapsed/refractory a number of myeloma: DREAMM-5 research design. Future Oncol. 17, 1987–2003 (2021).
Sommer, C. et al. Preclinical analysis of ALLO-605, an allogeneic BCMA turbocar TTM cell remedy for the therapy of a number of myeloma. Blood 136, 8–8 (2020).
Lee, D. W. et al. ASTCT consensus grading for cytokine launch syndrome and neurologic toxicity related to immune effector cells. Biol. Blood Marrow Transpl. 25, 625–638 (2019).
Kumar, S. et al. Worldwide Myeloma Working Group consensus standards for response and minimal residual illness evaluation in a number of myeloma. Lancet Oncol. 17, e328–e346 (2016).
Prevention and Remedy of Most cancers-Associated Infections (Model 1.2021). NCCN Scientific Follow Tips in Oncology, July 2 (Nationwide Complete Most cancers Community, 2021).